[ET Net News Agency, 17 December 2024] CCB initiates coverage of Biostar Pharm (02563)
with a target price of HKD35.85 and an "outperform" rating.
The research house said a likely catalyst for Biostar Pharma is the potential approval
of its oral formulation of Utidelone for the China market by end-4Q25F. (rc)
Future News
17/12/2024 15:35
{I-bank focus}CCB starts Biostar Pharm (02563) at HKD35.85
Previous︰17/12/2024 16:25 HSI ends down 95 pts at 19,700; TEH down 25 pts at 4,389
Next︰17/12/2024 15:18 {Block Trade}HAO TIAN INTL: 37.17m shares, or HK$23.79m
17/12/2024 16:35 Short Selling Turnover (Main Board) up to day close(1)
17/12/2024 16:31 Spot month fut dn 74 pts to 19747, premium 47 pts to HSI
17/12/2024 16:28 HK$ markets: Overnight Hibor at 3.70%; US$/HK$ 7.7700/05
17/12/2024 15:06 {Block Trade}CHINA MOBILE (00941): 583k shares, or HK$43.84m
17/12/2024 15:05 {B-shares}SSE B-shares dn 2.7%; SZSE B-shares dn 0.9%